Top

Annals of Hematology

Published in:

01-12-2020 | Blastic Plasmacytoid Dendritic Cell Neoplasm | Letter to the Editor

Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm

Authors: Matthew Schwede, Irena T. Tan, Danielle F. Atibalentja, Meghan M. Dickman, Kerri E. Rieger, Gabriel N. Mannis

Published in: Annals of Hematology | Issue 12/2020

Excerpt

Dear Editor, …

Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, Orfeuvre H, Corront B, Feuillard J, Sotto JJ, Bensa JC, Brière F, Plumas J, Jacob MC (2001) Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97:3210–3217. https://doi.org/10.1182/blood.v97.10.3210CrossRefPubMed

Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101:5007–5009. https://doi.org/10.1182/blood-2002-10-3297CrossRefPubMed

Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F, Dalle S (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169:579–586. https://doi.org/10.1111/bjd.12412CrossRefPubMed

Feuillard J, Jacob M-C, Valensi F, Maynadié M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drénou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, le Calvez G, Sainty D, Sotto MF, Trimoreau F, Béné MC (2002) Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 99:1556–1563. https://doi.org/10.1182/blood.v99.5.1556CrossRefPubMed

Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F, for GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party) (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98:239–246. https://doi.org/10.3324/haematol.2012.072645CrossRefPubMedPubMedCentral

Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M (2019) Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med 380:1628–1637. https://doi.org/10.1056/NEJMoa1815105CrossRefPubMed

Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA (2017) Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov 7:156–164. https://doi.org/10.1158/2159-8290.CD-16-0999CrossRefPubMed

Grushchak S, Joy C, Gray A, Opel D, Speiser J, Reserva J, Tung R, Smith SE (2017) Novel treatment of blastic plasmacytoid dendritic cell neoplasm. Medicine (Baltimore) 96:e9452. https://doi.org/10.1097/MD.0000000000009452CrossRef

DiNardo CD, Rausch CR, Benton C et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93:401–407. https://doi.org/10.1002/ajh.25000CrossRefPubMed

Title: Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm
Authors: Matthew Schwede
Irena T. Tan
Danielle F. Atibalentja
Meghan M. Dickman
Kerri E. Rieger
Gabriel N. Mannis
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keyword: Blastic Plasmacytoid Dendritic Cell Neoplasm
Published in: Annals of Hematology / Issue 12/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04276-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2020

A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis

Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09)

Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma

Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma

Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page